

It's "ja-pie-go!" - *nice to meet you!*

Reflections on intersections between HPV vaccination and HIV prevention and care programs

Chris Morgan, Technical Director Immunization


April 2024

**Saving lives.
Improving health.
Transforming futures.**

Johns Hopkins University Affiliate



Jhpiego's perspective: a Johns Hopkins University affiliate – with wide geographic footprint, programs across HIV, RMNCH, Immunization (esp HPV)



4,373 staff
 supporting **104**
 projects in
40+ countries

Jhpiego's Life-course Vaccination and Integration Experience

- **HPV vaccination for girls aged 9 – 14**
 - Past support to introductions in *Côte d'Ivoire, Liberia* and *Zambia*
 - Various support to *Kenya, Côte d'Ivoire, Tanzania, Pakistan* and the *Philippines*
- **COVID-19 vaccination roll-out**
 - Support to introductions in 19 countries
 - HIV teams working on VMMC and other efforts reaching adults were pivotal
- **Malaria vaccine introductions technical support**
 - Support to introductions in *Burkina Faso, Liberia* (ongoing) and *Cote d'Ivoire* (anticipated)
 - Integration with broader malaria control a key feature of our support
- **Maternal immunization**
 - Maternal Immunization Readiness Initiative *Kenya* and *Bangladesh* completing in early 2024,
- **Integrated service delivery**
 - *Tanzania's* successful HPV-Plus incorporates *adolescent health with HPV vaccine* in schools
 - *Integrating vaccination with cervical cancer control*, in the *Philippines* and *Thailand*
 - *India* – integrating *adolescent vaccination* with school health programs implications for HPV



www.stophpv.org




Funding from USAID, BMGF, Gavi and other partners



194 Countries have introduced HPV vaccine in national schedules, but coverage lags

HPV vaccine included in national immunization programme



Mean of programme coverage in the region/world

Region	HPV1 (%)
AFRO	51
AMRO	45
EMRO	43
EURO	65
SEARO	45
WPRO	57

Global	HPV1 (%)
Global	55

Disclaimer

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.




© WHO 2024. All rights reserved.



HPV Vaccination for immuno-compromised populations, including living with HIV

- Recognizes higher prevalence of high-risk HPV infections among girls and women living with HIV,
- Good HIV treatment control is critical
- Sufficient immuno-protective response to those vaccines that are *both* currently “pre-qualified” by WHO for use *and* supplied through Gavi:
 - › Bivalent: Cervarix and Cecolin
 - › Quadrivalent: Gardasil4
- Safety in this population well assured
- WHO now allows the option of a single-dose schedule for *general* populations (of major programmatic benefit), *but*
- Those living with HIV should receive at least two doses, and where possible three doses.
- In LMICs this has proven challenging to institute and we currently lack data on how well we are doing



The image shows a screenshot of the WHO Weekly epidemiological record page for HPV vaccines. The page is in French and includes the WHO logo, the title 'Weekly epidemiological record / Relevé épidémiologique hebdomadaire', and the date '16 DECEMBER 2022, 97th YEAR / 16 DÉCEMBRE 2022, 97^e ANNÉE'. The main article is titled 'Human papillomavirus vaccines: WHO position paper (2022 update)'. The page is divided into sections: 'Contents', 'Sommaire', 'Introduction', and 'Introduction'. The 'Introduction' section discusses the WHO's mandate to provide normative guidance to Member States on health policy matters, WHO issues a series of regularly updated position papers on vaccines and combinations of vaccines against diseases that have an international public health impact. These papers are concerned primarily with the use of vaccines in large-scale vaccination programmes. The vaccine position papers are drafted by the WHO SAGE Secretariat; they summarize essential background information on diseases and vaccines and conclude with the current WHO position on the use of the vaccines worldwide. Before finalization, the position papers are reviewed by a large group of external subject-matter experts and end-users. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) and the evidence-to-recommendation tables are published alongside the position paper. The methods followed by SAGE and the processes for preparation of vaccine position papers are described on the WHO website. The position papers are intended for use by national public health officials and managers of immunization programmes. They may also be of interest to other stakeholders.

Contents
645 Human papillomavirus vaccines: WHO position paper (2022 update)

Sommaire
645 Vaccins contre les papillomavirus humains: note de synthèse de l'OMS (mise à jour de 2022)

Human papillomavirus vaccines: WHO position paper (2022 update)

Introduction
In accordance with its mandate to provide normative guidance to Member States on health policy matters, WHO issues a series of regularly updated position papers¹ on vaccines and combinations of vaccines against diseases that have an international public health impact. These papers are concerned primarily with the use of vaccines in large-scale vaccination programmes.

The vaccine position papers are drafted by the WHO SAGE Secretariat; they summarize essential background information on diseases and vaccines and conclude with the current WHO position on the use of the vaccines worldwide. Before finalization, the position papers are reviewed by a large group of external subject-matter experts and end-users. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) and the evidence-to-recommendation tables are published alongside the position paper. The methods followed by SAGE² and the processes³ for preparation of vaccine position papers are described on the WHO website. The position papers are intended for use by national public health officials and managers of immunization programmes. They may also be of interest to other stakeholders.

Vaccins contre les papillomavirus humains: note de synthèse de l'OMS (mise à jour de 2022)

Introduction
Conformément à son mandat, qui prévoit qu'elle fournisse aux États Membres des orientations à caractère normatif en matière de politique sanitaire, l'OMS publie une série de notes de synthèse¹ régulièrement mises à jour sur les vaccins et les associations vaccinales contre les maladies ayant une incidence sur la santé publique internationale. Ces notes portent principalement sur l'utilisation des vaccins dans le cadre de programmes de vaccination à grande échelle.

Les notes de synthèse sur les vaccins sont rédigées par le secrétariat du SAGE de l'OMS; elles résument les informations essentielles sur les maladies et les vaccins associés et présentent en conclusion la position actuelle de l'OMS concernant l'utilisation de ces vaccins à l'échelle mondiale. Avant leur mise en forme définitive, elles sont examinées par un large groupe d'experts externes et d'utilisateurs finals. Les résultats de l'évaluation GRADE (Grading of Recommendations Assessment, Development and Evaluation) et les tableaux des données à l'appui des recommandations sont publiés en même temps que la note de synthèse. Les méthodes employées par le SAGE² et la procédure suivie³ pour élaborer les notes de synthèse sur les vaccins sont décrites sur le site Web de l'OMS. Les notes de synthèse sont destinées aux responsables nationaux de la santé publique et aux administrateurs des programmes de vaccination à grande échelle.

Reflections on the intersections between HIV and HPV vaccine programs

What can HIV do for HPV?

- Ensure up-to-date vaccination (including HPV) is part of HIV care programs
 - › Noting extra doses needed for those living with HIV
- Draw lessons from HIV programs reaching adolescents to improve HPV program outreach
- Contribute to HPV vaccine registers and other health information systems
- Boost access to the screening and treatment that saves lives now



Berenice, Côte d'Ivoire. Used with permission

What can HPV do for HIV?

- Clarify policy and practice in HPV vaccination for those living with HPV
- Provide job-aids and communication tools on HPV vaccine rationales
- Communicate information on key health issues, and services available (including those relevant to HIV prevention and care) during HPV vaccination.
- Improve HIV-specific coverage estimates, consistent with privacy



Girls who have received HPV-Plus
in Njombe/Makete District
Council-Ugabwa Primary School,
Tanzania

Thank you!

christopher.morgan@jhpiego.org